

## **Alphora Research Inc. Announces \$4M Capital Program for 2011**

Alphora is pleased to announce a \$4 million capital program for 2011, providing further expansion of its facilities and capabilities for API technology development, to meet growing client demand. Investments are being made across all areas, with a focus on R&D, cGMP Operations, Analytical Services and Alphora plans to grow to over 90 people.

Alphora recently secured new research facilities, allowing a 50% increase in its process chemistry R&D capacity.

Isolation technology is also being added to support growing efforts with High Potency compounds. This investment includes the addition of 3 separate isolators and will continue to reinforce Alphora's experience for developing High Potency API's.

Additional analytical equipment is planned for the expansion. A key addition will be a GC/MS system, emphasizing Alphora's capabilities in API characterization and control of Genotoxic Impurities (GTI's).

Alphora also plans further expansion of its cGMP operations in 2011.

A fourth cGMP Kilo Lab will be constructed, equipped with a 60L Buchi glass lined cryogenic vessel and supporting equipment. The kilo lab will have a dedicated HEPA filtered heating and ventilation system and pressure locks suitable for class 100,000 use.



Significant additions are also being made to Alphora's warehousing capacity. A 10,000 square foot expansion is planned for 2011, providing new storage facilities for API's, intermediates, raw materials and solvents. This expansion is in advance of a second Pilot Plant, which is planned for 2012.

Alphora is also installing a new Enterprise Resource Planning (ERP) system to provide greater control and flexibility to its plant operations.

These expansions represent a significant investment for Alphora and reinforce the company's capabilities in API Technology Development, ensuring its clients continue to receive "the right development at the right time" through phase appropriate solutions.

Alphora provides API technology development services to the Pharmaceutical and Biotechnology industry that include process chemistry, analytical services as well as cGMP scale-up capabilities.

Founded in 2003 by Dr. Jan Oudenes, Alphora Research has worked closely with its clients to deliver numerous clinical stage materials, as well as conducted validation efforts in advance of market launch. Alphora's FDA inspected operations total 45,000 sq. ft. and include synthetic laboratories, analytical laboratories, cGMP stability studies, cGMP kilo laboratories and a cGMP Pilot Plant.

For additional information on this news release or about Alphora, please contact:

Geoff Evans,  
Vice President, Business Operations

OR

Matt Frizzle  
Account Manager, Business Development